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Abstract
Nonalcoholic fatty liver disease (NAFLD) is believed to be the most common chronic liver disease, affecting at least
one-third of the population worldwide. The more aggressive form is known as nonalcoholic steatohepatitis (NASH)
and characterized by hepatocyte necrosis and inflammation. The presence of fibrosis is not uncommon. Fibrosis
indicates a more aggressive course and patients with NASH that are at high-risk of cirrhosis and premature mortality, as
well as at increased risk of hepatocellular carcinoma (HCC). Patients with type 2 diabetes mellitus (T2DM) are at the
highest risk for the development of NASH, even in the setting of normal plasma aminotransferase levels. The presence of
dysfunctional adipose tissue in most overweight and obese subjects, combined with insulin resistance, hyperglycemia,
and atherogenic dyslipidemia, contribute to their increased cardiovascular risk. Many therapeutic agents have been
tested for the treatment of NASH but few studies have focused in patients with T2DM. At the present moment, the only
FDA-approved agents that in controlled studies have shown to significantly improve liver histology in patients with
diabetes are pioglitazone and liraglutide. Current research efforts are centering on the mechanisms for intrahepatic
triglyceride accumulation and for the development of steatohepatitis, the role of mitochondrial dysfunction in NASH,
and the impact of improving glycemic control per se on the natural history of the disease. This brief review summarizes
our current knowledge on the pharmacological agents available for the treatment of NASH to assist healthcare providers
in the management of these challenging patients.
Keywords: Nonalcoholic fatty liver disease (NAFLD), Nonalcoholic steatohepatitis (NASH), Type 2 diabetes mellitus,
Insulin resistance, Metformin, Thiazolinediones, Pioglitazone, Dipeptidyl peptidase 4 (DPP-4) inhibitors, Glucagon-like
peptide-1 receptor agonists (GLP-1RA), Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Background
Nonalcoholic fatty liver disease (NAFLD) is the most
common liver disease in the United States [1], affecting
about 60–70 % of all obese individuals. With one-third
of adults being obese, and a similar proportion being
overweight, a large number of Americans are at risk of
developing the disease [2]. The future magnitude of the
problem can be better appreciated knowing that more
than one-third of the pediatric population is overweight
or obese [3]. Nonalcoholic fatty liver disease encom-
passes a broad spectrum of disease severity, ranging
from isolated steatosis to its more severe form with vari-
able degrees of hepatocyte inflammation, necrosis and
liver fibrosis, known as nonalcoholic steatohepatitis
(NASH) [4, 5]. Of note, among the histologic features of
NASH, fibrosis is the more strongly correlated with end-
stage liver disease and increased mortality [6, 7]. The
presence of obesity and insulin resistance, often with
clinical features of the metabolic syndrome (but not ne-
cessarily), leads to a high-risk profile for the develop-
ment of NAFLD. However, it is the presence of T2DM
that confers the highest risk for NAFLD, and specially,
for NASH. The highest mortality in NAFLD/NASH
arises not from end-stage liver disease, or an increased
risk of hepatocellular carcinoma (HCC), but secondary
to cardiovascular disease [8, 9]. This may be explained
by worse atherogenic risk factors such as hyperglycemia,
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hyperinsulinemia [10] and dyslipidemia [11], among
others.
Unfortunately, in the clinical setting, the lack of a reli-
able non-invasive diagnostic blood test or imaging tech-
nique for its diagnosis has let to underestimate the true
prevalence of this condition. The prevalence of NAFLD
in the general population is 34 % measured by the gold-
standard technique of magnetic resonance and spectros-
copy (1H-MRS), but about 2-fold higher in obese pa-
tients [12]. In a recent study in obese patients with
T2DM and normal liver aminotransferases, the preva-
lence of NAFLD was 56 % and more than half of those
undergoing a liver biopsy had NASH [13]. A population-
wide liver biopsy study examining the prevalence of
NASH in T2DM is not available given the invasive na-
ture of the procedure. However, in a recent study in
3041 patients from the Rotterdam Study, a population-
based study among individuals ≥45 years of age, Koehler
et al. [14] reported that one out of six patients with
T2DM had a diagnosis of fibrosis using a combined
non-invasive screening approach of liver ultrasound and
liver transient elastography. Taken together, it has be-
come evident that NASH is a significant risk factor for
future severe liver and cardiovascular disease. There is a
need for increased awareness among clinicians to diag-
nose and treat early-on these patients.
Role of dysfunctional adipose tissue and lipotoxicity
The pathophysiology of NAFLD is complex and multi-
factorial [1, 15, 16]. In the context of obesity and T2DM
(both highly prevalent in NAFLD), mitochondrial dys-
function, insulin resistance and adipose tissue inflamma-
tion play a major role. It is well established that white
adipose tissue is an active endocrine organ with potential
to have major metabolic effects [17]. Adipose tissue se-
cretes a diversity of adipokines that can have a pro- or
anti-inflammatory effects [18, 19]. Obesity is commonly
linked with adipose tissue activation of macrophages that
promote a proinflammatory state and a state of subclin-
ical inflammation that is also typical in patients with
NAFLD. The presence of dysfunctional adipose tissue
leads to increased rates of lipolysis and flux of free fatty
acids to ectopic tissues activating apoptotic pathways
and/or generating subsequent insulin resistance in
muscle and liver [20]. The development of a “lipotoxic
state” in NASH is central to activation of inflammatory
pathways that lead to hepatocyte necroinflammation,
and potentially a major target for therapy, as will be dis-
cussed in the next section.
Therapeutic interventions
Diet and lifestyle modification
Many studies have been done in NAFLD involving lifestyle
modification and/or weight loss by dietary modification
only. Most studies report a reduction in plasma amino-
transferases and often improvement in hepatic steatosis.
However, the data is often from small, poorly controlled
studies and have rarely focused on patients with T2DM.
Also, most have used surrogate endpoints to assess liver
improvement, such as plasma aminotransferases or liver
ultrasound, and rarely liver histology [21, 22]. A number
of recent studies quantifying hepatic steatosis by 1H-MRS
indicate that a modest weight reduction in the range of 5–
10 % with exercise alone, or combined with caloric restric-
tion, significantly reduces intrahepatic triglycerides
(IHTG) by about 40 % [20]. In general, reduction in IHTG
content (and improvement in cardiovascular risk factors)
is proportional to the magnitude of weight loss induced by
lifestyle intervention, as well demonstrated in a substudy
of the Look Ahead that quantified hepatic triglycerides by
1H-MRS [23]. For instance, patients losing 5 to 10 % of
weight had a 65 % decrease in IHTG, while the few
achieving a ≥10 % lost 80 %. Similar results were reported
by Wong et al. [24] after lifestyle intervention in a 12-
month RCT in 154 patients with NAFLD, where a signifi-
cant 5.6 kg total body weight reduction was associated
with a 55 % decrease in IHTG (liver triglyceride content
changing from 12.3 to 5.5 %). Unfortunately, the impact on
liver histology was not examined in either study, but
Promrat et al. [25] did report that a reduction of total
body weight of ≥9 % is associated with a broad histological
improvement in steatosis, necrosis and inflammation in
patients with NASH. Patients with NASH undergoing bar-
iatric surgery also have in most cases a reduction of
hepatic steatosis, hepatocyte necrosis and inflammation,
with less certain effects on fibrosis [26, 27]. However, im-
provement in fibrosis by weight loss or lifestyle changes is
less well established and no specific dietary plan (other
than caloric restriction) appears to be uniquely beneficial
in NASH. The weight loss agents phentermine/topira-
mate, lorcaserin and naltrexone/bupropion have not
undergone careful testing in a RCT in patients with
NASH, but they may likely assist in improving histology
as they may decrease body weight by ~10 % at maximal
doses. In any case, improvement in dietary habits and in-
creased physical activity leading to weight loss are funda-
mental interventions for the treatment of both T2DM and
NAFLD.
Pharmacological agents
Many agents have been tested for the treatment of
NASH but most not specifically in patients with T2DM.
For instance, agents that modify cholesterol metabolism
such as statins or ezetemibe have been extensively stud-
ied [28, 29]. Statins can be safely given to patients with
NAFLD/NASH to reduce their increased cardiovascular
risk [30]. Several small studies have suggested some
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benefit of statins in NAFLD/NASH, although usually
they have been short-term, uncontrolled trials using sur-
rogate primary end points (such as plasma aminotrans-
ferases or imaging) rather than liver histology. No
histological improvement was reported when comparing
statin therapy versus placebo in the only 12-month con-
trolled study using liver histology as the primary end-
point [31]. Taken together, there is consensus that
statins do not improve hepatocyte ballooning or fibrosis
in NASH, but are safe to prevent cardiovascular disease
in this population. Ezetimibe may decrease IHTG, but
its efficacy to improve steatohepatitis is unknown [32].
Omega-3 polyunsaturated fatty acids (PUFAs) activate
peroxisome proliferator-activated receptor (PPAR) α re-
ceptors, which upregulate several genes involved in fatty
acid oxidation, holding potential to reduce hepatic steato-
sis and downregulate pro-inflammatory pathways in
NAFLD/NASH. While small, uncontrolled studies have
reported a reduction in plasma aminotransferases and
liver steatosis, recent studies with omega-3 fatty acids have
been negative [33–36]. In summary, there appears to be
no major role for PUFAs for the treatment of NASH.
Vitamin E is an anti-oxidant believed to reduce hep-
atocyte oxidative stress in patients with NASH [1]. In
non-diabetic patients with biopsy-proven NASH vitamin
E led to significant histological improvement in the pri-
mary endpoint (improvement in ≥2 grades in the
NAFLD activity score [NAS], including hepatocellular
ballooning and with no worsening of fibrosis), compared
to placebo (p = 0.001) [37]. However, resolution of
NASH did not reach statistical significance (36 % vs.
21 %, p = 0.05), an endpoint only reached in the same
study by pioglitazone (47 %, p = 0.001 vs. placebo). Vita-
min E also did not significantly improve histology in a
large RCT in a pediatric population with NASH, al-
though some histological features did improve (i.e., he-
patocellular ballooning) [38]. In summary, vitamin E
may be beneficial in patients with NASH without T2DM
because it is relatively inexpensive and at the dose used
(800 IU per day) it appears to be safe [39, 40]. However,
its long-term efficacy has not been established in NASH
and it has not been tested in patients with T2DM.
Pentoxifylline is a non-selective phosphodiesterase in-
hibitor that may decrease inflammatory pathways in
NASH, such as TNF-α [28]. Several open-label, small
studies reported mixed results on plasma aminotransfer-
ases and hepatic steatosis on imaging [41]. Two small
12-month studies have reported on histology. While in
one study in 30 patients with NASH pentoxifylline did
not improve histology compared to placebo [42], another
small trial (n = 20 patients) reported some improvement
in steatosis, lobular inflammation and fibrosis after 1
year [43]. More work is clearly needed to define its role
in NAFLD and in patients with T2DM, a population
never studied with this agent.
Metformin
Metformin is considered first-line therapy for the manage-
ment in T2DM given its ability to improve insulin action
and lower plasma glucose without hypoglycemia, as well
as its potential for weight loss [44]. Given that patients
with NAFLD/NASH have insulin resistance, it has been
extensively tested in this setting. Early studies suggested
histological benefit, but this was likely more related to
concomitant weight loss in uncontrolled studies than to
the biguanide per se [45, 46] (Table 1). For instance, in the
study by Loomba et al. [45], the correlation of histological
improvement with weight loss was very high (r = 0.79, p <
0.0001), and improvement in the NAFLD activity score
happened largely in patients that lost ≥5 % of body weight
(i.e., in four out of five patients). More recently, similar
negative results were also reported in a RCT in 173 chil-
dren (mean age: 13 years) assigned to either metformin
1000 mg, vitamin E 800 U or placebo for 96 months [38].
Several recent meta-analysis have included better-
controlled studies and have concluded that metformin is
Table 1 Therapeutic agents for T2DM and their effect NAFLD/NASH in clinical trials
Treatment Mechanism of action AST/ALT Liver fat by imaging Liver histology
Oral
Metformin [38,45-48] Insulin-sensitizer ↓ ↓*,↔^ Unchanged
Pioglitazone [52, 53, 55] PPARγ agonist ↓ ↓^ Improved
Sitagliptin [72, 80, 81] DPP-4 inhibitor ↓ n/a n/a
Vildagliptin [82] DPP-4 inhibitor ↓ ↓^ n/a
Canagliflozin [90] Inhibits renal glucose reabsortion ↓ n/a n/a
Dapagliflozin [91, 92] Inhibits renal glucose reabsortion ↓ n/a n/a
Injectable
Exenatide [70] GLP-1 receptor agonist ↓ ↓^ n/a
Liraglutide [69-75] GLP-1 receptor agonist ↓ ↓**,^ Improved
*NAFLD assessed by ultrasound, **NAFLD assessed by CT, ^NAFLD assessed by MRI/1H-MRS, n/a: data not available
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not effective for the treatment of NASH [47, 48]. However,
it must be highlighted that all glucose-lowering drugs ap-
proved for the treatment of type 2 diabetes are safe in
NAFLD/NASH, unless advanced cirrhosis. Metformin is
not liver-metabolized but largely eliminated by renal clear-
ance, and can can be used safely in the vast majority of pa-
tients with NASH.
Thiazolinediones: role of pioglitazone
Thiazolinediones (TZDs) are ligands for the transcrip-
tion factor PPAR-γ that plays a key role in the regulation
of glucose and lipid metabolism, as well as in inflamma-
tion [49]. PPAR-γ is predominately expressed in adipose
tissue, but is also present in many other tissues that
regulate metabolic pathways such as the pancreas, liver
and muscle. At least part of the mechanism of action of
TZDs relates to restoring normal adipose tissue biology.
Treatment with TZDs is associated with an amelioration
of proinflammatory adipokines and an increase in the se-
cretion of adiponectin by adipocytes [50], restoring the
response of adipose tissue to insulin action, as well as at
the level of the liver and skeletal tissue [20]. Evidence for
the long-term impact of these broad metabolic and anti-
inflammatory effects can be appreciated in the potential
for pioglitazone to prevent the progression to T2DM in
patients with impaired glucose tolerance, improving not
only plasma glucose levels but also blood pressure and
lipid levels [51], all factors that play an important role in
the morbidity and mortality of patients with T2DM.
Both pioglitazone and rosiglitazone have been tested
in patients with NASH [47]. Early studies were small,
uncontrolled and reported mixed clinical results [20, 47]
Belfort et al. [52], in a proof-of-concept 6-month trial in
patients with prediabetes and T2DM, reported the first
RCT of pioglitazone (plus a -500 kcal/day caloric re-
stricted diet) in patients with biopsy-proven NASH. Pa-
tients had a significant improvement in hepatic steatosis,
and necroinflammation. The NAFLD activity score
(NAS) improved in 73 % of patients treated with pioglit-
azone compared to only 24 % in the placebo group with
diet alone (p < 0.001). There was also a suggestion that
fibrosis could be reversed in NASH, as pioglitazone-
treated patients had a significant reduction in liver fibro-
sis compared to baseline, although this fell short of
reaching statistical significance when compared to pla-
cebo (p = 0.08). This study was important in establishing
that the histological abnormalities present in NASH
could potentially be halted, and even reversed, within a
relatively short period of time. Two additional RCTs
later extended these findings to patients with NASH but
without diabetes [37, 53], but rosiglitazone proved to be
rather ineffective [54]. Recently, Cusi et al. [55] reported
a 36-month study in 101 patients with prediabetes or
T2DM and NASH. They found sustained histological
and metabolic benefit with long-term treatment. Of
note, there was also a modest but statistically significant
difference in the mean scores for fibrosis when com-
pared to placebo. The fact that improvement persisted
over time suggests that pioglitazone may modify the nat-
ural history of the disease [56]. Treatment was well tol-
erated, with only mild weight gain (2.5 kg versus
placebo). Potential side effects associated with TZDs in-
clude weight gain from either improved insulin action in
adipocytes with increased triglyceride synthesis and
overall adiposity, or rarely, from fluid retention. Devel-
opment of shortness of breath or congestive heart failure
is rare (~1 % or less) in the setting of pioglitazone treat-
ment, and is related to unknown diastolic dysfunction
that is common in T2DM. Finally, mild bone loss may
occurr in women [49]. Recently, Lewis et al. [57] demon-
strated in a long-term prospective study lack of an asso-
ciation between pioglitazone and bladder cancer. Of
note, TZDs treatment has been associated with a reduc-
tion in a broad spectrum of cancers [58, 59] and with a
decrease in cardiovascular mortality [60].
Glucagon-like peptide-1 (GLP-1) receptor agonists
GLP-1 receptor agonists (GLP-1RA) may become an at-
tractive therapeutic option for the treatment of patients
with T2DM and NASH given their broad spectrum of
effects on glucose and lipid metabolism. Their structure
prevents them from being immediately cleaved and inac-
tivated by circulating dipeptidyl peptidase (DPP)-4
prolonging their systemic actions. Glucose-lowering by
GLP-1RA is attributed to enhancement of insulin secre-
tion, reduction of postprandial glucagon concentration,
effects at the level of the central nervous system with ap-
petite suppression and induction of weight loss, as well
as improvement of insulin action in hepatocytes and adi-
pose tissue [61]. It has been proposed that there may be
direct binding to hepatic GLP-1 receptors that may ac-
count for at least part of the beneficial metabolic action
in the liver [62–64]. A number of animal studies have
shown that GLP-1 analogs improve hepatic insulin sensi-
tivity and decrease steatosis [62, 64–66], and even fibro-
sis [67]. Exendin-4 significantly reduces hepatic de novo
lipogenesis (DNL) in vitro and in vivo [68]. This is im-
portant as increased DNL is believed to play a significant
role in NAFLD.
Several studies hinted at a potential benefit of GLP-1RA,
but evidence until recently was inconclusive. A significant
decrease in plasma aminotransferase levels and hepatic
steatosis (assessed by CT scan) was observed at the higher
dose of liraglutide (1.8 mg) in a meta-analysis of 6 RCT
LEAD (Liraglutide Efficacy and Action in Diabetes) trials
[69]. However, this difference was not significant after ad-
justment for weight (p = 0.25) or A1c (p = 0.93), suggesting
an effect primarly associated with these factors. In an early
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study, Cuthberson et al. [70] found that 6 months of GLP-
1RA therapy (19 with exenatide and 6 with liraglutide) was
associated with significant weight loss of 5.0 kg, a 1.6 %
A1c reduction and a 42 % relative reduction in IHTG (all
p < 0.001). The relative reduction in IHTG correlated with
A1c (r = 0.49; p = 0.01), but not significantly with change in
total body weight, visceral or subcutaneous adipose tissue.
Similar findings have been reported in other small uncon-
trolled studies [71, 72]. Eguchi et al. [73] also reported a
reduction in body mass index (BMI), visceral fat accumula-
tion, aminotransferases and hyperglycemia in 19 patients
with biopsy-proven NASH treated with liraglutide for
24 weeks, with histological improvement in 6 out of 10
who had a repeat liver biopsy after 96 weeks of liraglutide
treatment. Finally, in a recent uncontrolled study while
both insulin glargine and liraglutide similarly decreased
A1c levels, only insulin significanty decreased IHTG from
baseline [74]. However, the study was hampered by the
small sample size (n = 35) and significant number of drop-
outs (~20 %), short duration of follow-up (3 months) and
the low-dose of liraglutide used (1.3 mg/day).
In the most comprehensive study to date, the LEAN
(Liraglutide Efficacy and Action in Non-alcoholic steato-
hepatitis) trial showed benefit when 52 patients with
biopsy-proven NASH were treated for 48 weeks with lira-
glutide at a dose of 1.8 mg per day [75]. Only one-third of
the population had T2DM, but overall patients were obese
and had evidence of insulin resistance. After treatment,
39 % of patients that received liraglutide had resolution of
NASH (defined as disappearance of hepatocyte ballooning
without worsening of fibrosis) compared to only 9 % in
the placebo arm. While fibrosis did not improve with lira-
glutide, more patients in the placebo arm experienced
worsening of fibrosis (p = 0.04). Patients treated with lira-
glutide had a significant reduction of body weight, fasting
plasma glucose and A1c levels. A subset of patients ac-
cepted to undergo in-depth glucose and lipid turnover
studies before and after 12 weeks of liraglutide treatment.
This resulted in improved insulin sensitivity at the level of
the liver, as well as a decrease in hepatic DNL. Insulin ac-
tion in adipose tissue also improved, both fasting and in
response to low-dose insulin infusion (i.e., suppression of
systemic and with directly measured subcutaneaous mi-
crodialysis techniques). However, the improvements in in-
sulin sensitivity were overall modest, and confounded by
weight loss. Moreover, enhanced adipose tissue insulin
sensitivity was not observed (i.e., Adipo-IRindex) when the
entire cohort was analyzed [75].
Taken together, treatment of patients with T2DM and
NAFLD with GLP-1RA is an approach that calls for lar-
ger, long-term studies, to fully understand their thera-
peutic potential and the role of mechanisms that
account for their efficacy beyond weight reduction or
amelioration of hyperglycemia.
Dipeptidyl peptidase-4 (DPP-4) inhibitors
An alternate therapetic option for the treatment of
NAFLD in T2DM are DPP-4 inhibitors. Their mechan-
ism of action is primarily from the blockade of the
multifunctional protein DPP-4 that degrades glucagon-
like peptide-1 (GLP-1) and plays a key role in postpran-
dial glucose homeostasis [76, 77]. These pharmacolgical
agents primarily lower the postprandial plasma glucose
(~50 mg/dl) and reduce A1c levels by ~0.6 to 0.8 % [78].
Also animal studies have shown their ability to reduce
liver triglyceride content and inflammation [79].
The role of these agents in NAFLD has been tested in
short-term clinical trials. Reduction in plasma aminotrans-
ferases have been reported with sitagliptin in Japanese pa-
tients with T2DM and NAFLD [72, 80]. In contrast, in
another study plasma aminotransferases did not improve in
patients with biopsy-proven NAFLD treated with sitagliptin
for 12 months [81]. In a 6-month RCT in 44 patients
with T2DM, Macauley et al. [82] reported that vilda-
gliptin 50 mg twice daily significantly decreased plasma
alanine aminotransferase (ALT) levels (from 27 to
20 IU/L, p < 0.001) and IHTG by 1H-MRS (from 7.3 %
to 5.3 %, p = 0.001). Of note, plasma ALT was not truly
elevated at baseline. Moreover, IHTG were only mildy
increased before treatment (normal considered to be
≤5.5 %). However, a robust correlation was found be-
tween a decrease in the plasma aminotransferases and
the triglyceride liver content (r = 0.83; p < 0.0001), con-
firming the close correlation between liver triglyceride
content and plasma ALT [83]. In this study, there was
no improvement in liver, muscle or adipose tissue insu-
lin sensitivity. Reduction in IHTG did not correlate
with changes in body weight but rather with the de-
crease in fasting plasma glucose at 3 months (r = 0.47;
p = 0.02) and 6 months (r = 0.44; p = 0.03).
It should be noted that overall, the effect of DPP-4 in-
hibitors appears to be modest, although large RCTs with
histological endpoints are lacking to conclusively estab-
lish their role in patients with T2DM and NASH.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
These agents inhibit the reabsorption of glucose in the
proximal tubular system with a marked reduction of
plasma glucose levels [84, 85]. At the present moment
three agents are approved: dapagliflozin, canagliflozin
and empagliflozin. Their use is also associated with a
reduction of total body weight, possibly as a secondary
effect of caloric loss and increased diuresis [86]. Re-
cently, empagliflozin has been associated with a reduc-
tion in cardiovascular mortality [87].
Studies performed in rodents have shown that SGLT2
inhibitors, in addition to the reduction of plasma glucose
concentration, decrease hepatic triglyceride accumula-
tion and other inflammatory biomarkers [88, 89]. While
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these agents are now well-established therapeutic agents
for the treatment of T2DM, their specific impact in
NAFLD remains to be determined. The administration
of canagliflozin (100 or 300 mg per day) for 52 weeks is
associated with a reduction in plasma liver aminotrans-
ferases, especially at the higher dose, but their impact on
liver histology is unknown [90]. While a small study did
not see such en effect with dapagliflozin [91], Bailey
et al. [92] reported a reduction in plasma ALT concen-
tration in a larger 24-week trial. Considering that these
pharmacologic agents ameliorate hyperglycemia, induce
weight loss, and may improve insulin sensitivity, they are
actively being explored for the treatment of NAFLD/
NASH in patients with T2DM.
Future treatments
Awareness about the high prevalence and significant
health risks associated with NASH in patients with T2DM
has led in recent times to a major drug discovery effort in
this field. As a result, a variety of clinical trials are being
conducted for the treatment of NASH, as reviewed else-
where [93, 94]. For instance, the FLINT study found bene-
fit with the treatment of obeticholic acid, a farnesoid X
receptor (FXR), compared to placebo [95]. Recently,
results from the GOLDEN 505 trail, a PPAR α/δ agonist,
believed to combine the benefits on lipid metabolism of a
PPARα and the effects on insulin sensitivity of PPARδ
agonist, failed to meet the primary endpoint of resolution
of NASH but reported some histological benefit in
patients with a higher NAS score (≥4) [96].
Conclusions
The presence of NASH is common among patients with
T2DM, putting them at risk of end-stage liver disease,
HCC and cardiovascular disease. Physicians must in-
crease their awareness about the high-risk of complica-
tions associated with NAFLD/NASH and the emerging
broad spectrum of therapeutic options. Lifestyle modifi-
cation is essential. While a Mediterranean diet has been
advocated to be beneficial, well-designed controlled
studies are needed [97] and the best diet for the long-
term management of NAFLD remains uncertain. Caloric
restriction with weight loss ≥10 % appears to be essential
for histological response. The addition of pharmacologic
agents early-on, especially pioglitazone, has the potential
to improve the quality of life and prevent severe comor-
bidities in this population.
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